"...In California and Washington state, San Francisco-based Omada Health is testing a version of Prevent, a diabetes and heart disease prevention program that's been modified for "underserved" populations – basically people on Medicaid or who are uninsured. The free program offers patients a digital scale as well as behavior counseling and education, access to a personal health coach and an online peer network.
To adapt the program, the company made it available in Spanish and English and lowered its reading level from ninth grade to fifth grade. Bilingual health coaches were hired, and the educational materials now acknowledge potential food access, neighborhood safety and economic issues that participants may face, said Eliza Gibson, Omada's director of Medicaid and safety-net commercial development.
The scale doesn't require a wireless connection, and the patient just needs to be able to access the Internet for one hour each week, Gibson said.
Omada is enrolling 300 community clinic patients in Southern California and rural Washington in a year-long clinical trial of Prevent, in hopes that the program can demonstrably slow the progress of diabetes."
Read More: http://www.npr.org/sections/health-shots/2016/06/23/483098999/the-challenge-of-taking-health-apps-beyond-the-well-heeled
Via: PR Newswire
The MDEAs took place June 14, in conjunction with MD&M East, happening this week in New York City
NEW YORK, June 15, 2016 /PRNewswire/ -- The Medical Design Excellence Awards (MDEA), recognizing the technological achievements of medical device manufacturers, announced the 2016 winners at a special ceremony on the evening of June 14. Produced by Medical Device and Diagnostic Industry (MD+DI), the awards ceremony honored innovation across nine categories, announcing gold, silver and bronze medal winners in each category, plus naming the best in show and revealing the readers' choice winner. The 2016 MDEA ceremony was held in conjunction with Medical Design & Manufacturing (MD&M) East, which is taking place this week at the Jacob K. Javits Convention Center in New York, NY.
Silk Road Medical Announces Updated Clinical Data on TCAR Presented at the 2016 Society for Vascular Surgery Annual Meeting
Via: PR Newsire
Presentations from the ROADSTER Study Highlight the Continued Safety, Efficacy and Durability of TransCarotid Artery Revascularization
SUNNYVALE, Calif., June 15, 2016 /PRNewswire/ -- Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, announced that the 2016 Vascular Annual Meeting of the Society for Vascular Surgery (SVS) held June 8-11 in National Harbor, MD featured six presentations on the company's ENROUTE® Transcarotid Neuroprotection and Stent System, the first and only products specifically designed and indicated for TransCarotid Artery Revascularization (TCAR).
Shire Receives FDA Breakthrough Therapy Designation for SHP621 and SHP625, Investigational Products for Rare Gastrointestinal Conditions
Update on Meritage Program:
Via: NEJM Catalyst
"....Outset Medical, based in San Jose, California, seeks to empower dialysis patients through technology.
CAMBRIDGE, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- Metabolix, Inc. (NASDAQ:MBLX) announced today that it has entered into an amendment to its license agreement with Tepha, Inc., a Lexington, Massachusetts based medical device company that licenses Metabolix PHA biopolymer technology for use in certain medical applications. The amendment calls for a $2.0 million lump sum payment to Metabolix. In exchange, Metabolix agreed to forgo future royalties under its existing license agreement with Tepha and to provide two additional Metabolix production strains and related intellectual property to Tepha for use in the production of Tepha's medical devices.
NEW YORK, New York, May 5, 2016 — Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that the Company has launched a new website, CiraraStories.com, which will feature people afflicted by this devastating condition – patients, their families, and the medical professionals who care for them.
OncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the AACR Annual Meeting 2016
REDWOOD CITY, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new biomarker research associated with its clinical programs for anti-RSPO3 (OMP-131R10) and vantictumab (anti-FZD7, OMP-18R5), as well as new preclinical mechanism-of-action data for demcizumab (anti-DLL4, OMP-18M21), at the American Association of Cancer Research (AACR) Meeting. All three presentations support ongoing clinical trials: anti-RSPO3 in a Phase1a/b trial in advanced solid tumor and colorectal cancer; vantictumab in a Phase 1b trial in pancreatic cancer; and demcizumab in a Phase 2 randomized study in first-line non-small cell lung cancer (NSCLC).
REDWOOD CITY, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new data related to its GITRL-Fc immuno-oncology therapeutic candidate at the American Association of Cancer Research (AACR) Meeting. OncoMed plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its GITRL-Fc candidate in late 2016/early 2017.
Silk Road Medical Announces FDA 510(k) Clearance and First Patients Treated in the US with the Next Generation ENROUTE® Transcarotid Neuroprotection System
Via: Yahoo! Finance
System Designed Specifically for Novel TransCarotid Artery Revascularization (TCAR) Procedure to be Immediately Launched in the United States